• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors.

作者信息

Henke M M, Richly H, Drescher A, Grubert M, Alex D, Thyssen D, Jaehde U, Scheulen M E, Hilger R A

机构信息

Universitatsklinikum Essen, Essen, Germany.

出版信息

Int J Clin Pharmacol Ther. 2009 Jan;47(1):58-60. doi: 10.5414/cpp47058.

DOI:10.5414/cpp47058
PMID:19203540
Abstract
摘要

相似文献

1
Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors.反式[四氯双(1H-吲唑)-钌(III)]/吲唑盐酸盐(1:1.1)(FFC14A)钠在实体瘤患者中的药代动力学研究
Int J Clin Pharmacol Ther. 2009 Jan;47(1):58-60. doi: 10.5414/cpp47058.
2
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.一种新型抗癌钌配合物（KP1019，FFC14A）在I期剂量递增研究中的药代动力学
Anticancer Drugs. 2009 Feb;20(2):97-103. doi: 10.1097/CAD.0b013e328322fbc5.
3
Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.通过毛细管区带电泳测定抗肿瘤吲唑盐[反式-四氯双(1H-吲唑)钌(III)]与血清转运蛋白的结合比较
Anal Biochem. 2005 Jun 15;341(2):326-33. doi: 10.1016/j.ab.2005.03.020.
4
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.KP1019，一种新型氧化还原活性抗癌药物——临床前研究及肿瘤患者一期临床研究结果
Chem Biodivers. 2008 Oct;5(10):2140-2155. doi: 10.1002/cbdv.200890195.
5
KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview.KP1019（FFC14A）从实验室到临床应用：临床前和早期临床开发——综述
Int J Clin Pharmacol Ther. 2005 Dec;43(12):595-6. doi: 10.5414/cpp43595.
6
X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.与人类血清白蛋白结合的吲唑鎓反式-[四氯双(1H-吲唑)钌(III)](KP1019)的X射线结构分析揭示了两个钌结合位点，并为药物结合机制提供了见解。
J Med Chem. 2016 Jun 23;59(12):5894-903. doi: 10.1021/acs.jmedchem.6b00600. Epub 2016 Jun 7.
7
Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.利用毛细管电泳与电感耦合等离子体质谱联用技术阐明临床试验中一种抗癌钌配合物与生物分子的相互作用。简短通讯。
Chem Biodivers. 2008 Aug;5(8):1609-1614. doi: 10.1002/cbdv.200890148.
8
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).从实验室到临床——抗癌药物反式-[四氯双(1H-吲唑)钌(III)] 吲哚鎓盐（KP1019或FFC14A）的临床前及早期临床开发
J Inorg Biochem. 2006 May;100(5-6):891-904. doi: 10.1016/j.jinorgbio.2006.02.013. Epub 2006 Feb 28.
9
Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE.使用毛细管电泳法探究细胞外还原剂存在下血清蛋白-钌（III）药物加合物的稳定性。
Electrophoresis. 2007 Jul;28(13):2235-40. doi: 10.1002/elps.200600707.
10
Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.毛细管电泳-电感耦合等离子体质谱法研究铂族金属药物与蛋白质的结合：进一步深入了解新型抗肿瘤钌（III）配合物与人血清蛋白的反应性
Electrophoresis. 2006 Mar;27(5-6):1128-35. doi: 10.1002/elps.200500694.

引用本文的文献

1
Exploring Serum Transferrin Regulation of Nonferric Metal Therapeutic Function and Toxicity.探索血清转铁蛋白对非铁金属治疗功能和毒性的调节作用。
Inorganics (Basel). 2020 Sep;8(9). doi: 10.3390/inorganics8090048. Epub 2020 Aug 29.
2
Metallo-Drugs in Cancer Therapy: Past, Present and Future.金属药物在癌症治疗中的应用：过去、现在和未来。
Molecules. 2022 Oct 1;27(19):6485. doi: 10.3390/molecules27196485.
3
Controversial Role of Transferrin in the Transport of Ruthenium Anticancer Drugs.转铁蛋白在钌类抗癌药物转运中的争议性作用。
Biomolecules. 2022 Sep 18;12(9):1319. doi: 10.3390/biom12091319.
4
Modification of Aβ Peptide Aggregation via Covalent Binding of a Series of Ru(III) Complexes.通过一系列钌（III）配合物的共价结合对β-淀粉样蛋白肽聚集的修饰
Front Chem. 2019 Dec 3;7:838. doi: 10.3389/fchem.2019.00838. eCollection 2019.
5
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry.NAMI-A 和 KP1019/1339，两个标志性的钌类抗癌候选药物面对面：药物无机化学的案例研究。
Molecules. 2019 May 24;24(10):1995. doi: 10.3390/molecules24101995.
6
Ruthenium-based chemotherapeutics: are they ready for prime time?钌类化疗药物：它们是否已经准备好成为主流？
Cancer Chemother Pharmacol. 2010 May;66(1):1-9. doi: 10.1007/s00280-010-1293-1. Epub 2010 Mar 6.